| dc.creator |
Russell, G |
|
| dc.creator |
Starr, S |
|
| dc.creator |
Elphick, C |
|
| dc.creator |
Rodogno, R |
|
| dc.creator |
Singh, I |
|
| dc.date |
2017-11-08T14:48:19Z |
|
| dc.date |
2017-10-31 |
|
| dc.date |
2017-11-08T14:48:19Z |
|
| dc.identifier |
Published online 31 October 2017 |
|
| dc.identifier |
10.1111/hex.12637 |
|
| dc.identifier |
http://hdl.handle.net/10871/30211 |
|
| dc.identifier |
Health Expectations |
|
| dc.description |
This is the final version of the article. Available from Wiley via the DOI in this record. |
|
| dc.description |
BACKGROUND: Guidelines suggest the patient community should be consulted from the outset when designing and implementing basic biomedical research, but such patient communities may include conflicting views. We examined how engagement occurred in one such instance. OBJECTIVE: Our objective was to scrutinize patient and public involvement (PPI) by a pan-European biomedical consortium working to develop drugs to treat autism. We aimed to use this as an example to illustrate how PPI has been utilized in biomedical research. SETTING, PARTICIPANTS AND ANALYSIS: Two public events, one in the UK and one in Denmark were conducted as part of the consortium's on-going PPI activities in 2014 and 2015. Sixty-six individuals submitted written comments on the consortium's research after these events. The textual data produced were analysed using a thematic approach. Approximately 71% of respondents reported themselves to be adults on the autism spectrum or parents of children with autism. RESULTS: The themes identified illustrated major differences between some community concerns and the biomedical research agenda. While treating autism per se. was seen as problematic by some, treating specific co-occurring problems was seen as helpful in some circumstances. The biomedical consortium selected PPI with a limited user viewpoint at its outset and more widely once basic research was on-going. DISCUSSION: This case illustrates what we term "selective PPI" where only a sympathetic and/or limited patient viewpoint is included. Findings highlight the perils of using selective PPI to legitimise scientific endeavours, and the possibilities for constructive dialogue. |
|
| dc.description |
This work was supported by EU-AIMS (European Autism Interventions), which receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115300, the resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (grant FP7/2007-2013); The first author's work was specifically funded by the Wellcome Trust, Grant number 108676/Z/15/Z. |
|
| dc.language |
en |
|
| dc.publisher |
Wiley |
|
| dc.relation |
https://www.ncbi.nlm.nih.gov/pubmed/29090494 |
|
| dc.rights |
© 2017 The Authors. Health Expectations Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
|
| dc.subject |
PPI |
|
| dc.subject |
autism |
|
| dc.subject |
biomedicine |
|
| dc.subject |
patient and public involvement |
|
| dc.title |
Selective patient and public involvement: The promise and perils of pharmaceutical intervention for autism |
|
| dc.type |
Article |
|